1. O’Donnell JA, Gelone SP. Fluoroquinolones. Infect Dis Clin North Amer 2000; 14: 489–513.
2. Blondeau JM. Expanded activity and utility of the new fluoroquinolones: a review. Clin Ther 1999; 21 (1): 3–40.
3. Падейская Е.Н., Яковлев В.П. Антимикробные препараты группы фторхинолонов в клинической практике. М.: ЛОГАТА, 1998.
4. Яковлев В.П., Падейская Е.Н., Яковлев С.В. Ципрофлоксацин в клинической практике. М.: Информэлектро, 2000.
5. Saravolatz L, Manzor O, Check C et al. Antimicrobial activity of moxifloxacin, gatifloxacin and six fluoroquinolones against Streptococcus pneumoniae. J Antimicrob Chemother 2001; 47: 875–7.
6. Schentag JJ. Pharmacokinetic and pharmacodynamic predictors of antimicrobial efficacy: moxifloxacin and Streptococcus pneumoniae. J Chemotherapy 2002; 14 (Suppl. 2): 13–21.
7. Blondeau JM, Felingham D. In vitro and in vivo activity of moxifloxacin against community respiratory tract pathogens. Clin Drug Invest 1999; 18 (1): 57–78.
8. Bartlett JG, Dowell SF, Mandell LA et al. Practice guidelines for the management of community-acquired pneumonia in adults. Clin Infect Dis 2000; 31: 347–82.
9. Niederman MS, Mandell LA, Anzueto A et al. American Thoracic Society: guidelines for the management of adults with community-acquired pneumoniae: diagnosis, assessment of severity, antimicrobial therapy and prevention. Am J Resp Crit Care Med 2001; 163: 1730–54.
10. Mandell LA, Marrie TJ, Grossman RE et al. Canadian guidelines for the initial management of community-acquired pneumonia. Clin Infect Dis 2000; 31: 383–421.
11. Woodhead M, Blasi F, Ewig S et al. Guidelines for the management of adult lower respiratory tract infections. Eur Respir J 2005; 26: 1138–80.
12. Katx E, Larsen L, Fogarty C et al. Safety and efficacy of sequential i.v. to p.o. moxifloxacin vs conventional combination therapies for the treatment of community-acquired pneumonia in patients requiring initial i.v. therapy. J Emerg Med 2004; 27: 395–405.
13. Torres A, Garau J, Arvis P et al. Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study – a randomized clinical trial. Clin Infect Dis 2008; 46: 1499–509.
14. Finch R, Colins O, Kubin R et al. Moxifloxacin IV/PO compared with amoxicillin/clavulanate IV/PO with or without clarithromycin in the treatment of community-acquired pneumonia. Clin Microbiol Infect 2001; 7 (Suppl. 1): 167.
15. Drummond M, Finch R, Duprat-Lomon I et al. Superior outcomes with moxifloxacin IV/PO monotherapy compared to IV/PO amoxicillin/clavulanate ± clarithromycin in the treatment of community-acquired pneumonia. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, USA, 16–19 Dec 2001.
16. Pechere J-C, Lacey L. Optimizing economic outcomes in antibiotic therapy of patients with acute bacterial exacerbation of chronic bronchitis. J Antimiсrob Chemother 2000; 45 (2): 19–24.
17. Moxon ER, Murphy TF. Haemophilus influenzae. In: Principles and practice of infectious diseases. Ed.: G.Mandell, J.Bennett, R.Dolin. 5th ed. Churchill Livingstone, Philadelphia. USA 2000; 2: 2369–78.
18. Murhy TF, Sethi S. Bacterial infection in chronic obstructive pulmonary disease. Am Rev Respir Dis 1992; 146: 1067–83.
19. De Abate CA, Mathew CP, Warner JH et al. The safety and efficacy of short course (5-day) moxifloxacin vs azithromycin in the treatment of patients with acute exacerbation of chronic bronchitis. Respir Med 2000; 94: 1029–37.
20. Wilson R, Allegra L, Huchon G et al. Short and long outcomes of moxifloxacin (MXF) compared to standard antibiotic treatment (STD) in acute exacerbations of chronic bronchitis (AECB). The MOSAIC study. Eur Resp J 2003; 22 (Suppl. 45): 35–59.
21. Yakovlev S, Dvoretsky L, Nonikov V et al. Comparative assessment of moxifloxacin and macrolides in acute exacerbation of chronic bronchitis: clinical efficacy and influence on the long-term prognosis. 14th European Congress of Clinical Microbiology and Infectious Diseases Prague. Czech Republic 2004. Abstr. P459.
22. Miravitlles M, Molina J, Brosa M et al. Clinical efficacy of moxifloxacin in the treatment of exacerbations of chronic bronchitis: a systematic review and meta-analysis. Arch Bronchopneumol 2007; 43 (1): 22–8.
23. Edmiston CE, Krepel CJ, Seabrook GR et al. In vitro activities of moxifloxacin against 900 aerobic and anaerobic surgical isolates from patients with intra-abdominal and diabetic foot infections. Antimicrob Agents Chemother 2004; 48 (3): 1012–6.
24. Hedberg M, Nord CE. Antimicrobial susceptibility of Bacteroides fragilis group isolates in Europe. Clin Microbiol Infect 2003; 9: 475–88.
25. Jonson J, Hoban D, Jordan S et al. Activity of moxifloxacin, metronidazole, and four other antimicrobial agents against anaerobic pathogens isolated from complicated intra-abdominal infections: data from an Asian clinical trial. 48th ICAAC. Washington 2008. Abstr. C1-1958.
26. Stass H, Rink AD, Delesen H et al. Pharmacokinetics and peritoneal penetration of moxifloxacin in peritonitis. J Antimicrob Chemother 2006; 58: 693–6.
27. Rink AD, Stass H, Delesen H et al. Pharmacokinetics and tissue penetration of moxifloxacin in interventional therapy of intra-abdominal abscess. Clin Drug Invest 2008; 28 (2): 1–9.
28. Wirtz M, Kleef J, Swoboda S et al. Moxifloxacin penetration into human gastrointestinal tissues. J Antimicrob Chemother 2004; 53: 875–7.
29. Malangoni MA, Song J, Herrington J et al. Randomized controlled trial of moxifloxacin compared with piperacillin-tazobactam and amoxocillin-clavulanate for the treatment of complicated intra-abdominal infections. Ann Surg 2006; 244 (2): 204–11.
30. Яковлев С.В., Рамишвили В.Ш., Назаров В.В., Еремина Л.В. Эффективность моксифлоксацина при вторичных перитонитах. Антибиотики и химиотерапия. 2006; 51 (5): 3–10.
31. Ross J, Cronje S, Paszkowski T et al. Moxifloxacin vs ofloxacin plus metronidazole in uncomplicated pelvis inflammatory disease: results of a multicenter, double blind, randomized trial. Sex Transm Infect 2006; 82: 446–51.
32. Heystek M, Ross JD. The PID Study Group. A randomized double-blind comparison of moxifloxacin and doxycycline/metronidazole/ciprofloxacin in the treatment of acute, uncomplicated pelvic inflammatory disease. Int J STD AIDS 2009; 20 (10): 690–5.
33. Ross J, Judlin P. 2012 European Guideline for the Management of Pelvic Inflammatory Disease, http://www.iusti.org/regions/europe/pdf/2012/PID_Treatment_Guidelines-Europe2012v5.pdf

М.П.Суворова

Кафедра госпитальной терапии №2 лечебного факультета ГБОУ ВПО Первый МГМУ им. И.М.Сеченова Минздрава России